Physician profile
David B Gropper
NPI 1720060445
$1,533.40
in general payments reported to CMS, 2019-2025
21 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $166 · 2021: $108 · 2022: $123 · 2023: $164 · 2024: $446 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $279.34 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $171.82 | 2023-2024 | Qelbree, Qelbree |
| Pfizer INC. | $157.90 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.56 | 2019-2024 | Eohilia |
| Verrica Pharmaceuticals INC. | $111.95 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $105.37 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Seqirus USA INC | $89.06 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $78.10 | 2020-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $73.28 | 2019-2020 | |
| Genentech USA, INC. | $54.26 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $48.58 | 2019 | |
| Kaleo, INC. | $47.79 | 2019-2024 | Auvi-Q |
| Adlon Therapeutics L.P. | $33.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.50 | 2019-2025 | Vaxneuvance, Proquad, Rotateq |
| Corium, LLC | $21.84 | 2025 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $21.52 | 2024 | Koselugo |
| Neos Therapeutics, Lp | $20.28 | 2024 | Adzenys Xr-Odt |
| Sobi, INC | $18.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.06 | 2025 | Zoryve |
| Shire North American Group INC | $16.44 | 2019 | |
| Phadia US INC. | $14.49 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gropper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.